Wss1 homolog from Candida albicans and its role in DNA-protein crosslink tolerance. Homchan A, Sukted J, Mongkolsuk S, Jeruzalmi D, Matangkasombut O, Pakotiprapha D. Mol Microbiol. 2020 Sep;114(3):409-422. doi: 10.1111/mmi.14518. Epub 2020 May 13. PMID: 32302440

28 Dec 2020
0
0

Wss1 homolog from Candida albicans and its role in DNA-protein crosslink tolerance.
Homchan A, Sukted J, Mongkolsuk S, Jeruzalmi D, Matangkasombut O, Pakotiprapha D.
Mol Microbiol. 2020 Sep;114(3):409-422. doi: 10.1111/mmi.14518. Epub 2020 May 13.
PMID: 32302440

Tags

Share this

Related Posts

Evaluation of anti-tumour properties of two depsidones – Unguinol and Aspergillusidone D – in triple-negative MDA-MB-231 breast tumour cells. Zwartsen, A., Chottanapund, S., Kittakoop, P., Navasumrit, P., Ruchirawat, M., Van Duursen, M. B. M. and Van den Berg, M. (2019). Toxicology Reports, 6, 1216-1222.
28 Dec 2019
0

Evaluation of anti-tumour properties of two depsidones – Unguinol and Aspergillusidone D – in triple-negative MDA-MB-231 breast tumour cells. Zwartsen, A., Chottanapund, S., Kittakoop, P., Navasumrit, P., Ruchirawat, M., Van Duursen, M. B. M. and Van den Berg, M. (2019). Toxicology Reports, 6, 1216-1222.

Evaluation of anti-tumour properties of two depsidones – Unguinol and Aspergillusidone D – in triple-negative MDA-MB-231 breast tumour cells. Zwartsen, A., Chottanapund, S., Kittakoop, P., Navasumrit, P., Ruchirawat, M., Van Duursen, M. B. M. and Van den Berg, M. (2019). Toxicology Reports, 6, 1216-1222.
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More